Sinco Pharmaceuticals Holdings Limited announced that the group expects to record a significant decline in profit for the six months ended 30 June 2016 as compared with that for the corresponding period in 2015. This is mainly attributable to the non-recurring expenses recognized during the reporting period of approximately RMB 17.5 million in connection with the listing of the shares of the Company on the main board of the Stock Exchange; and an increase in intermediary professional service fees incurred after the Listing in the amount of approximately RMB 2.1 million.